Overall survival (A), radiographic progression-free survival (B), and PSA progression-free survival (C), with and without baseline corticosteroid use.
CI, confidence interval; HR, hazard ratio (enzalutamide vs. placebo); NR, not reached; OS, overall survival; PSA, prostate-specific antigen; rPFS, radiographic progression-free survival; TTPP, time to PSA progression.